Janus Henderson Group
FDMT icon

Janus Henderson Group’s 4D Molecular Therapeutics FDMT Stock Holding History

Janus Henderson Group’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$48.9M Buy
5,247,151
+611,276
+13% +$5.32M 0.02% 417
2025
Q4 		$34.7M Buy
4,635,875
+2,882,508
+164% +$29.2M 0.02% 488
2025
Q3 		$15.2M Sell
1,753,367
-1,043
-0.1% -$6.23K 0.01% 666
2025
Q2 		$6.51M Sell
1,754,410
-137,525
-7% -$483K ﹤0.01% 827
2025
Q1 		$6.87M Sell
1,891,935
-360,305
-16% -$1.7M ﹤0.01% 792
2024
Q4 		$12.5M Sell
2,252,240
-884,847
-28% -$6.94M 0.01% 682
2024
Q3 		$33.9M Sell
3,137,087
-59,675
-2% -$990K 0.02% 467
2024
Q2 		$67.1M Sell
3,196,762
-682
-0% -$17.1K 0.04% 321
2024
Q1 		$102M Buy
3,197,444
+104,148
+3% +$2.66M 0.06% 263
2023
Q4 		$62.7M Buy
3,093,296
+346,961
+13% +$4.56M 0.04% 334
2023
Q3 		$35M Sell
2,746,335
-92,547
-3% -$1.55M 0.02% 432
2023
Q2 		$51.3M Buy
2,838,882
+961,457
+51% +$17.7M 0.03% 384
2023
Q1 		$32.3M Buy
1,877,425
+411,158
+28% +$8M 0.02% 473
2022
Q4 		$32.6M Sell
1,466,267
-1,173,195
-44% -$18.1M 0.02% 466
2022
Q3 		$21.2M Buy
2,639,462
+1,304,414
+98% +$11.8M 0.01% 659
2022
Q2 		$9.32M Sell
1,335,048
-330,363
-20% -$3.21M 0.01% 707
2022
Q1 		$25.2M Buy
1,665,411
+17,488
+1% +$275K 0.01% 692
2021
Q4 		$36.2M Buy
1,647,923
+126,820
+8% +$3.11M 0.02% 645
2021
Q3 		$41M Sell
1,521,103
-18,623
-1% -$531K 0.02% 609
2021
Q2 		$37.1M Buy
1,539,726
+312,329
+25% +$9.56M 0.02% 647
2021
Q1 		$50.7M Buy
1,227,397
+205,486
+20% +$9.1M 0.02% 546
2020
Q4 		$39.9M Buy
+1,021,911
New +$42.2M 0.02% 596

Other funds holding FDMT

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Janus Henderson Group's FDMT Position: Q1 2026 in Review

Janus Henderson Group increased its 4D Molecular Therapeutics (FDMT) stake by 13% in Q1 2026, buying an estimated $5.32M and bringing the position to 5,247,151 shares worth $48.9M. The position accounts for 0.02% of the portfolio, ranked #417.

Janus Henderson Group first reported a position in FDMT in Q4 2020 and has held it in 22 quarters since. The position peaked at $102M in Q1 2024. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Janus Henderson Group held 5,247,151 shares of 4D Molecular Therapeutics worth $48.9M as of Q1 2026.
  • Janus Henderson Group bought 611,276 4D Molecular Therapeutics shares in Q1 2026, an estimated $5.32M.
  • 4D Molecular Therapeutics made up 0.02% of Janus Henderson Group's portfolio in Q1 2026, its #417 holding.
  • Janus Henderson Group first reported a position in 4D Molecular Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Janus Henderson Group's 4D Molecular Therapeutics position peaked at $102M in Q1 2024.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.